Stem Cell Transplantation for Sickle Cell Anemia

Clinical Trial Summary

This protocol will be investigating the use of stem cell transplantation, in related donors, to cure sickle cell disease. Sickle cell disease is a recessive disorder caused by a point mutation that results in the substitution of valine for glutamic acid at the sixth position in the B-chain of hemoglobin. This leads to sickling of the red blood cells under many conditions, such as hypoxia, dehydration, and hyperthermia. The sickling leads to vaso-occlusion, which causes irreversible damage in almost all systems in the body, including the central nervous system (CNS), lungs, heart, bones, eyes, liver, and kidneys.

Primary objective: 1) To determine disease free survival (DFS) at two years after matched sibling transplant using bone marrow (BM) after a conditioning regimen consisting of distal timed Alemtuzumab, Fludarabine, and Melphalan for patients 2-30 y/o Secondary objectives: 1. Overall survival 2. Rate of neutrophil and platelet engraftment for BM 3. Incidence of graft failure 4. Incidence of grade II-IV and grade III-IV acute graft vs host disease (GVHD) 5. Incidence of chronic GVHD 6. Incidence of other transplant complications, such as veno-occlusive disease, central nervous system (CNS) toxicity, and idiopathic pneumonia syndrome (IPS) 7. Incidence of reactivation of CMV, EBV, adenovirus, BK/JC virus 8. Incidence of invasive fungal disease 9. Time to immune reconstitution via monitoring of lymphocyte subpopulations and immunoglobulin levels ;

Study Design

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease